Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

4 terminated/withdrawn out of 12 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
6(50.0%)
Phase 1
6(50.0%)
12Total
Phase 2(6)
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT00988169Phase 2Terminated

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Role: collaborator

NCT00934076Phase 1Withdrawn

Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer

Role: collaborator

NCT01265199Phase 1Terminated

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)

Role: lead

NCT00561197Phase 1Terminated

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

Role: lead

NCT00286793Phase 1Completed

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

Role: lead

NCT00275431Phase 2Completed

Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies

Role: lead

NCT00571675Phase 2Completed

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Role: lead

NCT00440388Phase 2Completed

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

Role: lead

NCT00544960Phase 2Completed

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

Role: lead

NCT00286806Phase 1Completed

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Role: lead

NCT00397293Phase 1Completed

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Role: lead

NCT00286780Phase 2Completed

Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

Role: lead

All 12 trials loaded